Concepedia

G. Cropp

GC

Statistics

Publications

27

Citations

1.3K

H-Index

18

Active since

1999

Affiliations

Dana-Farber Cancer Institute(Current)

Roswell Park Comprehensive Cancer Center

Arizona Oncology

The Ohio State University

Multiple Myeloma Research Foundation

G. Cropp is an author at Dana-Farber Cancer Institute specializing in pharmacology, cancer pharmacology, and medicine.

Publications per year

1999–2011

27

Publications

27

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Shanu Modi, Alison Stopeck, Michael S. Gordon et al. · Journal of Clinical Oncology · 2007 · 334 citations

, , +15

Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

Alison Stopeck, Marrae Sheldon, Mahmood Vahedian et al. · PubMed · 2002 · 151 citations

, , +16

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Bart C. Kuenen, Lee S. Rosen, Egbert F. Smit et al. · Journal of Clinical Oncology · 2002 · 140 citations

, , +17

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

Monica Mita, Matthew A. Spear, Lorrin Yee et al. · Clinical Cancer Research · 2010 · 107 citations

, , +16

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

S. Gail Eckhardt, Jinee Rizzo, Kevin Sweeney et al. · Journal of Clinical Oncology · 1999 · 71 citations

, , +17

1–5 of 27